2008
DOI: 10.1007/s12032-007-9036-9
|View full text |Cite
|
Sign up to set email alerts
|

A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer

Abstract: Our study involves a preliminary phase II trial, which evaluates the activity, feasibility and tolerability of a sequential combination of docetaxel and gemcitabine followed by docetaxel and carboplatin, as first-line treatment for inoperable NSCLC. Twenty-six chemo-naïve patients aged less than 75 years with histologically or cytologically confirmed unresectable stage IIIB, IV or relapsed post-operative metastatic NSCLC were included in the study. Gemcitabine 1,250 mg/m(2) was administered and was followed by… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2010
2010
2011
2011

Publication Types

Select...
3

Relationship

2
1

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…Most DT-associated HSR (95%) occur during the first or second infusion [6,18], and in some cases, it only takes 1 mg of DT for HSR to develop [19,20]. Symptoms include dyspnea or bronchospasm (81%), urticaria, flushing (74%), hypotension and angioedema [21,22]. Sudden death may occur [19].…”
Section: Introductionmentioning
confidence: 99%
“…Most DT-associated HSR (95%) occur during the first or second infusion [6,18], and in some cases, it only takes 1 mg of DT for HSR to develop [19,20]. Symptoms include dyspnea or bronchospasm (81%), urticaria, flushing (74%), hypotension and angioedema [21,22]. Sudden death may occur [19].…”
Section: Introductionmentioning
confidence: 99%